The latest type 2 diabetes (T2D) management guidance from the American Association of Clinical Endocrinology (AACE) covers ...

Novo Nordisk (NVO) stock gains after oral semaglutide pill succeeds in pediatric type 2 diabetes trial. Company targets H2 ...

April 23 (Reuters) - Novo Nordisk's oral GLP-1 drug significantly lowered blood sugar levels in children and adolescents with ...

Best known as a type 2 diabetes treatment, metformin is also being investigated for its possible effects on PCOS and ageing.

More than a quarter of people with Type 2 diabetes take GLP-1 receptor agonists, but the popular diabetes drugs might not work as well for people who have certain genetic variants, according to a new ...

Novo Nordisk's oral GLP-1 pill achieved its main target in a late-stage diabetes study involving children and adolescents ...

Emerging diabetes therapies are transforming MASLD treatment by addressing both metabolic dysfunction and liver disease, with new approvals and a growing pipeline signaling a shift in care. A rapidly ...

The latest experimental GLP-1 from Eli Lilly isn’t just a diabetes drug — it also facilitates weight loss. Known as “triple-G,” injectable retatrutide levies a triple whammy on the GLP-1, GIP and ...

BEIJING and BRIDGEWATER, N.J., April 9, 2026 /PRNewswire/ -- Gan & Lee Pharmaceuticals (hereinafter referred to as "Gan & Lee", SSE: 603087) announced the signing of an exclusive licensing agreement ...

Novo Nordisk said Wednesday that an experimental drug it is developing with Chinese pharmaceutical company The United Bio-Technology (Hengqin) Co. showed "positive" results with a mean body weight ...